tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MAZE Stock Latest News

Maze Therapeutics: Promising Future with Strong Pipeline and Robust Financial Health
RatingsMaze Therapeutics: Promising Future with Strong Pipeline and Robust Financial Health
5d ago
MAZE
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials
PremiumRatings
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Clinical Developments and Strategic Trials
7d ago
MAZE
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782
PremiumRatings
Maze Therapeutics: Promising Innovations in PKU and CKD Treatment with MZE782
7d ago
MAZE
Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15)
PremiumThe Fly
Maze Therapeutics reports Q2 EPS (77c), consensus ($1.15)
7d ago
MAZE
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock
PremiumRatings
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock
28d ago
MAZE
Maze Therapeutics initiated with a Buy at H.C. Wainwright
PremiumThe FlyMaze Therapeutics initiated with a Buy at H.C. Wainwright
28d ago
MAZE
Maze Therapeutics participates in a conference call with JPMorgan
Premium
The Fly
Maze Therapeutics participates in a conference call with JPMorgan
1M ago
MAZE
Wedbush bullish on Maze Therapeutics, initiates with an Outperform
Premium
The Fly
Wedbush bullish on Maze Therapeutics, initiates with an Outperform
1M ago
MAZE
Maze Therapeutics initiated with an Outperform at Wedbush
PremiumThe Fly
Maze Therapeutics initiated with an Outperform at Wedbush
1M ago
MAZE
Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position
PremiumRatings
Positive Outlook for Maze Therapeutics: Buy Rating Reiterated Amid Promising Drug Developments and Strong Financial Position
3M ago
MAZE
Positive Outlook for Maze Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating
PremiumRatings
Positive Outlook for Maze Therapeutics: Promising Pipeline and Strong Financial Position Justify Buy Rating
5M ago
MAZE
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year
PremiumThe Fly
Maze Therapeutics reports Q4 EPS ($18.32) vs ($11.46) last year
5M ago
MAZE
Block upgraded, Domino’s downgraded: Wall Street’s top analyst calls
PremiumThe FlyBlock upgraded, Domino’s downgraded: Wall Street’s top analyst calls
6M ago
AB
YY
Maze Therapeutics initiated with an Outperform at Leerink
Premium
The Fly
Maze Therapeutics initiated with an Outperform at Leerink
6M ago
MAZE
Maze Therapeutics initiated with a Buy at TD Cowen
Premium
The Fly
Maze Therapeutics initiated with a Buy at TD Cowen
6M ago
MAZE
Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics
PremiumRatings
Promising Drug Candidates and Market Potential Drive Buy Rating for Maze Therapeutics
6M ago
MAZE
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829
PremiumRatings
Maze Therapeutics, Inc.: Buy Rating Backed by Promising Pipeline and Lead Asset MZE829
6M ago
MAZE
Maze Therapeutics initiated with an Overweight at JPMorgan
PremiumThe Fly
Maze Therapeutics initiated with an Overweight at JPMorgan
6M ago
MAZE
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market
PremiumRatings
Maze Therapeutics: Strategic Positioning and Growth Potential in Genetic Disorders Market
6M ago
MAZE
Maze Therapeutics initiated with a Buy at Guggenheim
PremiumThe FlyMaze Therapeutics initiated with a Buy at Guggenheim
6M ago
MAZE
Maze Therapeutics doses first patient in Phase 2 HORIZON trial
Premium
The Fly
Maze Therapeutics doses first patient in Phase 2 HORIZON trial
6M ago
MAZE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >